Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer

Publication: British Journal of Cancer
UBC Author(s): Yvette Drew (Division of Medical Oncology / Faculty of Medicine)
ISSN: 00070920
Volume: 134
Page Range: 1754-1763
Publication Date: 20 June 2026